Leishen Energy
- Country
- 🇬🇧United Kingdom
- Ownership
- -
- Established
- 1895-01-01
- Employees
- 173
- Market Cap
- -
- Website
- https://www.lse.ac.uk/
- Introduction
Leishen Energy Holding Co., Ltd. engages in the provision of clean-energy equipment and integrated solutions to the oil and gas industry. It operates through the following business segments; Clean-Energy Equipment; Oil and Gas Engineering Technical Services; New Energy Production and Operation; Digitalization and Integration Equipment; The Clean-Energy Equipment segment supplies wellhead heating systems, wellhead safety control systems, oil-water separation systems, natural gas online sampling systems, oil and gas skid-mounted equipment and polymer flexible composite pipes. The Oil and Gas Engineering Technical Services segment provides customers with a products and technical solutions for oil and gas production. The New Energy Production and Operation segment focuses on the production, storage and transportation of natural gas, traditional fuels, development of distributed energy, and the planning and operation of new energy and new energy industries. The Digitalization and Integration Equipment segment designed to provide informatization solutions for industrial intelligence, mobility, industrial interconnection and big data trends. The company was founded by Hongqi Li in 2007 and is headquartered in Beijing, China.
Clinical Trials
12
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Communicating Multiple Uncertainties Associated With the Benefits and Risks of New Cancer Drugs
- Conditions
- Cancer
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- London School of Economics and Political Science
- Target Recruit Count
- 3000
- Registration Number
- NCT07110597
Effect of Communicating Structured Benefit and Harm Information in European Patient Leaflets on Individuals' Expectations About Medicines
- Conditions
- Cancer
- First Posted Date
- 2025-07-11
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- London School of Economics and Political Science
- Target Recruit Count
- 2100
- Registration Number
- NCT07061197
Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs
- Conditions
- Cancer
- First Posted Date
- 2025-05-30
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- London School of Economics and Political Science
- Target Recruit Count
- 3000
- Registration Number
- NCT06997185
- Locations
- 🇺🇸
Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, United States
Evaluating the Impact of a Digital Psychosocial Tool (Wysa) on Life Skills and Well-being of College Students in India
- Conditions
- WellbeingResilienceSelf EfficacyLife SkillsProblem Solving
- First Posted Date
- 2025-01-30
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- London School of Economics and Political Science
- Target Recruit Count
- 152
- Registration Number
- NCT06801093
- Locations
- 🇮🇳
Indian Institute of Technology, Gandhinagar (IIT-Gandhinagar), Palaj, Gujarat, India
Evaluation of a Comprehensive School Health Programme in Zambia
- Conditions
- MalariaDiarrheaAnemiaCoughHelminth InfectionUTISchistosomiasisSkin Rash
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- London School of Economics and Political Science
- Target Recruit Count
- 28700
- Registration Number
- NCT06560853
- Locations
- 🇿🇲
Chingola District Education Board, Chingola, Copperbelt, Zambia
🇿🇲Luanshya District Education Board, Luanshya, Copperbelt, Zambia
🇿🇲Masaiti District Education Board, Masaiti, Copperbelt, Zambia
- Prev
- 1
- 2
- 3
- Next
News
Medicare's First Drug Price Negotiations Yield Mixed Results: U.S. Prices Still Exceed International Levels
Medicare's first round of drug price negotiations achieved reductions ranging from 8% to 42% across ten medications, with sitagliptin showing the most significant price decrease.